Oncology Intelligence — June 23, 2026
| China’s NMPA cleared CARsgen’s satri-cel as the world’s first CAR-T for a solid tumor on the same day Pfizer’s first Seagen-derived ADC, sigvotatug vedotin, failed its pivotal NSCLC trial — a split-screen verdict on where cell therapy and ADC bets are paying off.
Today’s top developments:
|
What to Watch
- CARsgen’s ex-China path and earlier-line expansion — with satri-cel approved in China, watch whether CARsgen can secure FDA/EMA pathways and push into earlier-line and perioperative gastric cancer; its ongoing Phase 1 pancreatic study tests whether the CLDN18.2 CAR-T approach extends to other solid tumors.
- Pfizer’s Seagen pipeline prioritization — expect a pipeline prioritization update within the next two quarters, likely deprioritizing or out-licensing at least one Seagen ADC candidate following the sigvotatug vedotin NSCLC failure.
- Daraxonrasib’s confirmatory pancreatic readouts — Revolution Medicines must advance its confirmatory pancreatic cancer program over the next 12 months to sustain ASCO 2026 momentum before competing pan-RAS and G12D-selective KRAS programs generate their own pivotal data.
- AstraZeneca–Daiichi Sankyo as default NSCLC ADC beneficiary — datopotamab deruxtecan first-line data readouts in 2026–2027 are the key catalysts to watch as the partnership inherits NSCLC ADC share Pfizer fails to capture.
This brief highlights the edition’s top stories. Read the latest edition → for all stories and analysis.
